Hp 129Xenon Imaging for Bronchiolitis Obliterans Syndrome
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new imaging method using Hp 129Xenon gas to detect bronchiolitis obliterans syndrome (BOS) early in lung transplant patients. BOS is a serious condition affecting many lung transplant recipients. The trial aims to improve outcomes by diagnosing this condition sooner. Individuals who have had a lung transplant in the last 10 years or are considering one, and can hold their breath for 16 seconds, might be suitable for this trial. As a Phase 1, Phase 2 trial, the research focuses on understanding how the imaging method works in people and measuring its effectiveness in an initial, smaller group. Participants have the opportunity to contribute to early-stage advancements in BOS detection.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that this imaging method is safe for diagnosing bronchiolitis obliterans syndrome?
Research has shown that Hp 129Xenon is a safe and well-tolerated gas for lung imaging. Studies have found it effective in both healthy children and those with cystic fibrosis, a lung disease. These studies reported no major safety issues in either group. Participants inhaled doses similar to those planned for this trial without any serious problems. This provides strong evidence that Hp 129Xenon is generally safe for people.12345
Why are researchers excited about this trial?
Researchers are excited about Hp 129Xenon imaging for bronchiolitis obliterans syndrome because it offers a novel way to visualize lung function in real time. Unlike existing treatments, which focus primarily on managing symptoms with medications like corticosteroids or immunosuppressants, Hp 129Xenon provides a unique imaging technique using hyperpolarized xenon gas. This allows doctors to see detailed images of how air moves through the lungs, potentially leading to earlier and more precise diagnosis and monitoring of the disease. This innovative approach could revolutionize how we understand and treat this condition by offering insights that current therapies cannot provide.
What evidence suggests that Hp 129Xenon imaging is effective for diagnosing bronchiolitis obliterans syndrome?
Research has shown that Hp 129Xenon imaging, which participants in this trial will receive, can detect early lung changes linked to bronchiolitis obliterans syndrome (BOS). This non-invasive method does not require surgery or entering the body and uses a special type of xenon gas to create detailed MRI images of the lungs. Studies have found it safe and comfortable, even for children with lung issues like cystic fibrosis. By identifying problems early, this imaging technique might lead to better management and treatment of BOS. While it does not directly treat BOS, it could improve long-term health by allowing for earlier medical intervention.12356
Who Is on the Research Team?
Jason Woods, PhD
Principal Investigator
Children's Hospital Medical Center, Cincinnati
Are You a Good Fit for This Trial?
This trial is for people who had a lung transplant within the last decade or are being evaluated for one. They must be able to hold their breath up to 16 seconds. It's not suitable for those with bleeding disorders, claustrophobia, recent respiratory infections, pregnant individuals, or anyone who can't undergo MRI scans.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Biopsy
Participants undergo 129Xe MRI and image-guided bronchial biopsies to detect early BOS and understand disease progression
Follow-up
Participants are monitored for safety and effectiveness after imaging and biopsy procedures
Long-term Follow-up
Participants are followed up to 12 months post-transplant to capture MRI images for clinician assessment
What Are the Treatments Tested in This Trial?
Interventions
- Hp 129Xenon
Trial Overview
The study is testing Hp129 Xenon as a new imaging method aimed at early detection of Bronchiolitis Obliterans Syndrome (BOS), which affects many lung transplant recipients over time. The goal is to use these images to guide biopsies and help develop future treatments.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will inhale up to 4 doses of Hp129Xenon; each dose will be no more than 1 liter.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor
Published Research Related to This Trial
Citations
Hp 129Xenon Imaging for Bronchiolitis Obliterans Syndrome
This research may improve patient outcomes through earlier diagnosis of changes leading to BOS by obtaining image guided research biopsies of transplanted lung.
Feasibility, tolerability and safety of pediatric hyperpolarized ...
Hyperpolarized 129Xe is a safe and well-tolerated inhaled contrast agent for pulmonary MR imaging in healthy children and in children with cystic fibrosis who ...
MEARIS™ | Publication | ntap | NTP221017PBF9L - CMS
HP Xe 129 gas for oral inhalation with MRI offers an effective option for patients with pulmonary challenges to obtain quantitative information regarding their ...
Hyperpolarized 129Xe MRI for the Assessment of BOS ...
Hyperpolarized magnetic resonance imaging (MRI) is a novel and noninvasive functional imaging method, with the capacity to evaluate pulmonary structure and ...
Xenon-129 MRI detects ventilation deficits in paediatric stem ...
Bronchiolitis obliterans syndrome (BOS), the most common and severe later-onset pulmonary complication following HSCT, is an obstructive lung condition ...
Xenon-129 MRI detects ventilation deficits in paediatric ...
Regional lung ventilation abnormalities in paediatric HSCT patients were quantified using hyperpolarised xenon-129 ( 129 Xe) magnetic resonance imaging (MRI) ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.